Malignant adrenal gland pheochromocytoma

Summary

Malignant adrenal gland pheochromocytoma (MONDO:0006288) is a disease and 3 clinical trials. Top therapeutic interventions include lenvatinib and catequentinib hydrochloride. A subtype of neuroendocrine carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant adrenal gland pheochromocytoma
Mondo ID	MONDO:0006288
EFO	EFO:1000348
DOID	DOID:0080347
NCIT	C4220
SNOMED CT	21851000119103
UMLS	C0334419
MedGen	87238
GARD	0024362
Is cancer (heuristic)	no

Also known as: adrenal gland pheochromocytoma, malignant · malignant adrenal gland chromaffin neoplasm · malignant adrenal gland chromaffin paraganglioma · malignant adrenal gland chromaffin tumor · malignant adrenal gland chromaffin tumour · malignant adrenal gland Chromaffinoma · malignant adrenal gland paraganglioma · malignant adrenal gland pheochromocytoma · malignant adrenal medullary paraganglioma · malignant adrenal medullary pheochromocytoma · malignant adrenal pheochromocytoma · malignant pheochromocytoma · pheochromoblastoma · pheochromocytoma, malignant

Disease family

This is a subtype of neuroendocrine carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › neuroendocrine carcinoma › malignant adrenal gland pheochromocytoma

Related subtypes (11): small cell carcinoma, anal canal neuroendocrine neoplasm, large cell neuroendocrine carcinoma, pancreatic endocrine carcinoma, combined lung carcinoma, liver neuroendocrine carcinoma, medullary thyroid gland carcinoma, goblet cell carcinoma, cutaneous neuroendocrine carcinoma, thymic neuroendocrine carcinoma, vulvar neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03008369	PHASE2	COMPLETED	Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
NCT04860700	PHASE2	COMPLETED	The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
NCT02592356	Not specified	COMPLETED	Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LENVATINIB	4	2
CATEQUENTINIB HYDROCHLORIDE	3	1
CHEMBL5572229	0	1